Skip to main content
. 2017 Sep 28;8(54):92401–92410. doi: 10.18632/oncotarget.21359

Figure 1. Waterfall plots, the color keys indicate the best overall response by blinded independent review.

Figure 1

(A) the best percentage change in target lesion determined by RECIST 1.1 for all evaluable patients (N=55), and the dashed lines at 20% and -30% represent the progressive disease and partial response, respectively; (B) the best percentage change of CA19-9 in evaluable patients who had an elevated CA19-9 at baseline (N=52). Abbreviation: CR, completed response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available.